Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 9/7 cls
Biogen Idec (BIIB) Baird Christopher Raymond Price target Neutral 3% $65.78
Raymond raised his target to $68 from $60 after BIIB said it expects revenue

Read the full 381 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE